Implant Sciences Corp. a wholly-owned German subsidiary of CorNova, Inc., has received CE Mark marketing approval for its Valecor Coronary Stent System.
The cobalt-chromium stent is designed maximize flexibility and conformity while providing uniform expansion and coverage. Utilizing some of the thinnest struts of any commercialized coronary stent, the Valecor stent minimizes strut thickness, which is believed to play a significant role in reducing restenosis.
"We believe the passive coating technology we have developed with our strategic partner, CorNova, could have the potential to improve the biocompatibility of non-drug-eluting stents,” said Dr. Anthony J. Armini, PhD., CEO of Implant Sciences. “Combined with CorNova's drug-eluting polymer and other advanced endovascular technologies, we believe this could contribute to an advancement in drug eluting stent performance."
CE Mark approval allows the Valecor Coronary Stent System to be sold in all European Union countries as well as many other countries worldwide that accept this approval for registration. CorNova currently has sales and distribution offices in Munich, Germany and Buenos Aires, Argentina.
For more information visit www.implantsciences com.